Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EBT (2016 - 2025)

Amicus Therapeutics filings provide 16 years of EBT readings, the most recent being $3.1 million for Q4 2025.

  • On a quarterly basis, EBT fell 60.39% to $3.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $191000.0, a 100.66% increase, with the full-year FY2025 number at $191000.0, up 100.66% from a year prior.
  • EBT hit $3.1 million in Q4 2025 for Amicus Therapeutics, down from $34.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $34.3 million in Q3 2025 to a low of -$81.5 million in Q1 2022.
  • Median EBT over the past 5 years was -$36.1 million (2023), compared with a mean of -$33.1 million.
  • The widest YoY moves for EBT: up 405.14% in 2025, down 17860.19% in 2025.
  • Amicus Therapeutics' EBT stood at -$80.3 million in 2021, then rose by 12.72% to -$70.1 million in 2022, then surged by 54.82% to -$31.7 million in 2023, then soared by 125.06% to $7.9 million in 2024, then plummeted by 60.39% to $3.1 million in 2025.
  • The last three reported values for EBT were $3.1 million (Q4 2025), $34.3 million (Q3 2025), and -$19.2 million (Q2 2025) per Business Quant data.